Introduction
============

According to GLOBOCAN2012, lung cancer is the most common type of malignancy as well as the leading cause of cancer death worldwide.[@b1-ott-11-2509] Lung cancers can be categorized as central type or peripheral type by the location of primary lesions. Lung cancers can also be classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which can have significantly different prognosis and treatment strategies. Pulmonary adenocarcinoma (ADC) and squamous cell carcinoma (SQCC) are the most common pathologic types and account for 50% and 30% of NSCLC, respectively.[@b2-ott-11-2509] According to the literature, the majority of patients with central lung cancer have SCLC and SQCC. However, the proportion of central pulmonary ADC in central-type lung cancer has been gradually increasing due to the overall increasing incidence of pulmonary ADC.

With the development of advanced technologies, multiple diagnostic tools are available for detecting lung cancer. Among the many available tools, computed tomography (CT) is the most practical for screening and diagnosis due to its high resolution, convenience for follow-up and high benefit--cost ratio.[@b3-ott-11-2509],[@b4-ott-11-2509] Also, recent studies have revealed that radiological features in CT play a critical role in inferring histologic subtypes,[@b5-ott-11-2509]--[@b7-ott-11-2509] predicting treatment response[@b8-ott-11-2509] and determining patients' prognosis,[@b5-ott-11-2509],[@b9-ott-11-2509]--[@b11-ott-11-2509] in addition to differentiating malignant disease or staging established malignance. There have been several studies on the radiological characteristics and prognoses of central SCLCs and SQCCs,[@b5-ott-11-2509],[@b12-ott-11-2509]--[@b15-ott-11-2509] are rare. Furthermore, several studies have demonstrated that regional lymph node metastases and prognosis of patients with central ADC are different from those of patients with peripheral ADC.[@b16-ott-11-2509]--[@b19-ott-11-2509] The clinical and radiological characteristics of central ADCs and their impact on treatment response should be investigated to guide therapeutic strategies.

At present, there are no reports of the clinical and radiological characteristics of central ADCs. In this study, we compared the clinical and radiological features of central ADCs with those of central SQCCs and SCLCs. Moreover, we investigated the correlation between these features and the treatment response to first-line chemotherapy in patients with central ADC.

Patients and methods
====================

Patients
--------

This study was approved by the Institutional Review Board of Shandong Cancer Hospital, and all patients provided written informed consent for this study. We retrospectively reviewed the medical records of all patients with histologically confirmed primary lung cancer from July 2014 to September 2016. We selected patients who met the following criteria: 1) thoracic CT images acquired with our picture archiving and communication system before the patients received any treatment; 2) available clinical data including age, sex, smoking status, TNM stage (defined according to the eighth American Joint Committee on Cancer) and levels of tumor biomarkers (carcinoembryonic antigen \[CEA\], neuron-specific enolase \[NSE\] and cytokeratin 19 fragment \[Cyfra21-1\]); and 3) bronchoscopic findings or surgical resection, showing that the primary lesions were located in the region between the trachea and the segmental bronchi. There were 302 consecutive patients included in our study, comprising 99 patients with ADC, 95 patients with SQCC and 108 patients with SCLC. Of the 99 patients with central ADC, 7 underwent surgery, 7 received tyrosine kinase inhibitor and 85 received platinum-based chemotherapy with or without radiotherapy as the first-line therapy. Treatment response to first-line chemotherapy was determined by Response Evaluation Criteria In Solid Tumors 1.1. Also, patients were divided into response group (partial remission and complete remission) and nonresponse group (stable disease and progressive disease).

CT image acquisition
--------------------

CT scans were performed on CT systems (SIEMENS Soma-tom Definition AS; Siemens Medical Systems, Erlangen, Germany) with the following parameters: collimation, 64×0.6 mm; beam pitch, 1.5; tube voltage, 120 kVp and tube current, 200 mAs. The slice thickness of image reconstruction for lung parenchyma and mediastinum was 5 mm. CT images were reviewed with a 20.8 in. (52.8 cm), 2,048×31, 560 pixel grayscale monitor (Coronis3MP; Barco Display Systems, Kortrijk, Belgium). The lung window settings were as follows: window width, 1,600 HU, and window level, −600 HU. The mediastinal window settings were as follows: window width, 400 HU, and window level, 40 HU.

Visual interpretation of CT images
----------------------------------

Two radiologists (YH and LM with 24 and 17 years of experience, respectively) interpreted all CT images. Both radiologists were blinded to the pathologic types, and different opinions between the two radiologists were resolved by discussion until consensus was reached. Analysis of lung parenchyma was performed in accordance with the Fleischner Society Recommendations.[@b20-ott-11-2509] Tumor size (transverse maximum diameter), location (left vs right), margins (spiculated, lobulated), as well as presence of air bronchogram, bronchovascular bundle convergence, pulmonary infarction, lymphangitic carcinomatosis, pulmonary emphysema, lymphadenopathy (mediastinum, contralateral hilum, ipsilateral hilum), contralateral lung metastasis, pleural effusion and vascular involvement were recorded. Pleural nodules were defined as nodules or incrassation of either side of pleura, except for the pleura of interlobular fissure. According to Shim et al,[@b21-ott-11-2509] more than five fissural nodules or uneven fissural incrassation was indicative of interlobular fissure pleural metastasis.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software (version 22.0). Comparison of proportions of the categorical data among pathologic types was analyzed by *χ*^2^ or Fisher's exact test if appropriate. We analyzed the distribution of continuous quantitative data by Kolmogorov--Smirnov test. Continuous quantitative data were all non-normally distributed and compared among patients by Kruskal--Wallis test in our study. The optimal cutoff value of CEA level discriminating ADC from non-ADC (SQCC and SCLC) was calculated by using a receiver operating characteristic curve. Multinomial logistic regression analysis was performed to identify independent indicative factors for pathologic types of central lung cancers, and of central ADC group was performed as baseline. Univariate and multivariate logistic regression models were used to evaluate the association between the radiological characteristics and the treatment response to first-line chemotherapy in patients with central ADC. Variables witha a *p*-value of \<0.1 by univariate analysis were included in the multivariable model, which was adjusted for known predictive factors (sex, age, smoking status and tumor stage). A *p*-value of \<0.05 was considered to be statistically significant, while a *p*-value of \<0.0167 was considered to be statistically significant after Bonferroni correction.

Results
=======

Patient and demographic features
--------------------------------

There were 302 patients included in our study, with a median age of 61 years (range: 36--87). The demographic features are presented in [Table 1](#t1-ott-11-2509){ref-type="table"}. Male patients (n=213, 70.5%) and smokers (n=184, 60.9%) were predominant in our study. Also, most of the patients were at stage III or IV with the rates of 51.6% and 38.1%, respectively. But in contrast to our previous understanding of central lung cancers, in our study, ADC (n=99, 32.8%) was as prevalent as SQCC (n=95, 31.4%) and SCLC (n=108, 35.8%).

The association between clinical features and pathologic types
--------------------------------------------------------------

The associations between clinical features and pathologic types are presented in [Table 2](#t2-ott-11-2509){ref-type="table"}. Age (*p*=0.005), sex ratio (*p*\<0.001) and smoking status (*p*\<0.001) were significantly different among ADC, SQCC and SCLC patients. Female patients, younger patients and nonsmokers were more likely to have ADC rather than SQCC or SCLC. More importantly, the levels of CEA (*p*\<0.001), Cyfra21-1 (*p*\<0.001) and NSE (*p*\<0.001) also significantly differed among the three pathologic types. The levels of CEA were significantly higher in the central ADC group. The receiver operating characteristic analysis revealed that the area under the curve for CEA levels was 0.742 (95% CI 0.675--0.810; [Figure 1](#f1-ott-11-2509){ref-type="fig"}).

The association between radiological characteristics and pathologic types
-------------------------------------------------------------------------

As shown in [Table 3](#t3-ott-11-2509){ref-type="table"}, the majority of the morphologic characteristics on the CT images were significantly associated with the pathologic types, except for the location of primary lesion, presence of lobulated margin and ipsilateral hilum lymphadenopathy.

In contrast to non-ADC, ADC presented with more contralateral hilum lymphadenopathy (*p*\<0.001), contralateral lung metastasis (*p*\<0.001), pleural nodules (*p*\<0.001) and interlobular fissure pleural metastasis (*p*\<0.001). Several representative CT images of central ADC are presented in [Figure 2](#f2-ott-11-2509){ref-type="fig"}. Compared with NSCLC patients, SCLC patients had a larger mean maximal lesion size (*p*=0.001). Besides, both the rates of vascular involvement and pulmonary infarction were significantly different between NSCLC and SCLC (*p*\<0.001 and *p*\<0.001, respectively). Other significantly different radiological features among the three groups included the presence of spiculated margin (*p*=0.04), air bronchogram (*p*=0.02), bronchovascular bundle convergence (*p*=0.002), lymphangitic carcinomatosis (*p*=0.03), pulmonary emphysema (*p*=0.007) and pleural effusion (*p*\<0.001).

Multivariate analyses of pathologic types
-----------------------------------------

[Table 4](#t4-ott-11-2509){ref-type="table"} shows the clinical and radiological characteristics that independently discriminated SQCC and SCLC from ADC via multivariate analysis. Compared with central SQCC, female sex, younger age, no history of smoking, higher levels of CEA and contralateral hilum lymphadenopathy were found to be the significantly independent indicators of central pulmonary ADC on multivariate logistic regression analysis. Also, compared with central SCLC, younger age, higher levels of CEA and Cyfra21-1, lower levels of NSE, presence of pleural nodules and lack of vascular involvement were significantly and independently associated with central ADC.

The association between radiological characteristics of ADC and treatment response
----------------------------------------------------------------------------------

Among all patients with central ADC who received first-line platinum-based chemotherapy, the presence of pulmonary emphysema on the CT image was the only radiological feature that was significantly correlated with treatment response ([Table 5](#t5-ott-11-2509){ref-type="table"}). Multivariate logistic analysis revealed that the presence of pulmonary emphysema was correlated with a significantly poorer treatment response (odds ratio=8.04, 95% CI 1.39--46.37, *p*=0.02) independent of age, sex, smoking status and tumor stage.

Discussion
==========

In this study, we described the clinical and radiological characteristics of central pulmonary ADCs, compared them with those of patients with central SQCCs or SCLCs and correlated these features with the treatment response to first-line chemotherapy. Comparisons between central ADC and the other two pathologic types revealed distinct clinical and radiological profiles of central ADC. The presence of pulmonary emphysema was the only CT feature found to be an independent indicator of poorer treatment response to first-line chemotherapy in patients with central ADC.

With the increasing incidence of lung ADC, ADC has become the most common pathologic type of lung cancer worldwide.[@b22-ott-11-2509] This may explain why the incidence of ADC in our study was similar to that of SQCC and SCLC among all central-type lung cancers, which is different from our previous understanding. There have been several studies on the radiological characteristics and prognoses of central SCLCs and SQCCs,[@b5-ott-11-2509],[@b12-ott-11-2509]--[@b15-ott-11-2509] whereas studies on the clinical and radiological characteristics of central ADCs and their correlation with patients' outcomes are rare. By investigating the clinical and radiological characteristics of different pathologic types of central lung cancers, we can further understand their distinct biological behaviors and the impact they have on treatment response, allowing for the application of individualized therapeutic strategies.[@b5-ott-11-2509],[@b15-ott-11-2509]

Our results revealed that patients with central ADC were more likely to be female, be of younger age, have never smoked or have higher levels of CEA ([Table 2](#t2-ott-11-2509){ref-type="table"}). The presence of pleural effusion (n=55/99, 55.56%) and the presence of vascular involvement (n=32/99, 32.32%) were the common CT findings of central ADCs ([Table 3](#t3-ott-11-2509){ref-type="table"}). More importantly, we found that central ADCs presented more commonly with contralateral hilum lymphadenopathy, contralateral lung metastasis, pleural nodules and inter-lobular fissure pleural metastasis ([Table 3](#t3-ott-11-2509){ref-type="table"}) compared to the other two pathologic types. Meanwhile, contralateral hilum lymphadenopathy and pleural nodules were two independent radiological indicators for central ADC ([Table 4](#t4-ott-11-2509){ref-type="table"}). The distinctive clinical and radiological features of central ADCs may provide an auxiliary and noninvasive method for differential diagnosis.

There have been several studies comparing the clinical and radiological features among different pathologic types of lung cancers. Koenigkam Santos et al[@b5-ott-11-2509] found that compared to ADC, SQCC lesions were more central and less peripheral (43% for central SQCC vs 23% for ADC). In addition, SQCC presented a higher proportion of men, a higher age and less associated pleural tags, but no difference in lesion's diameter was found, which is consistent with the results of our study ([Table 3](#t3-ott-11-2509){ref-type="table"}). Furthermore, Koenigkam Santos et al also demonstrated that SQCCs showed less spiculated and more lobulated margins, and less commonly presented with internal air bronchogram compared to ADCs. These differences were also significant when comparing only peripheral lesions. However, in our study, no significant differences in these three CT signs were identified between patients with central ADC and SQCC ([Table 3](#t3-ott-11-2509){ref-type="table"}). More than half of the patients in the study by Koenigkam Santos et al had peripheral lung cancer, which may explain the differences in the results. Smith et al[@b6-ott-11-2509] found that the presence of emphysema was associated with SQCC (adjusted odds ratio 2.6, 95% CI 1.4--4.8) rather than ADC and SCLC after adjustment for age, sex, COPD and smoking history. The univariate analysis in our study also showed that SQCCs presented more commonly with emphysema compared to the other two pathologic types, but only the comparison with ADC was statistically significant. The study by Ren et al aimed to distinguish peripheral SCLCs (PSCLCs) from peripheral NSCLCs (PNSCLCs) using CT imaging[@b23-ott-11-2509] and found that there was no difference between PSCLCs and PNSCLCs in lesion size, and presence of air bronchogram and pleural effusion, but PNSCLCs presented with more spiculated signs and bronchovascular convergence signs. In our study, central NSCLCs comprised ADCs and SQCCs. The results of comparisons among central ADC, SQCC and SCLC ([Tables 3](#t3-ott-11-2509){ref-type="table"}[](#t4-ott-11-2509){ref-type="table"}--[5](#t5-ott-11-2509){ref-type="table"}) were not identical to those of PNSCLC and PSCLC[@b23-ott-11-2509] in both univariate analyses and multivariate analyses. This difference could be attributed to varying tumor characteristics, including the lesion location, the categories and the presence or absence of clinical variables. Therefore, it is necessary to differentiate central lung cancers from peripheral lung cancers.

Pulmonary emphysema is characterized pathologically by permanently enlarged airspaces distal to the terminal bronchiole with destruction of alveolar walls, and presents as focal areas or regions of low attenuation, usually without visible walls in CT.[@b20-ott-11-2509] In fact, the prognostic role of emphysema in NSCLC has been proven in several studies.[@b24-ott-11-2509]--[@b28-ott-11-2509] Gullon et al[@b25-ott-11-2509] retrospectively reviewed 353 patients with cytohistologic diagnosis of NSCLC and showed that emphysema (hazard ratio=1.49, 95% CI 1.11--2.01) was an independent prognostic factor. Although the presence of pulmonary emphysema was relatively infrequent in patients with central ADC compared to the other two groups ([Table 3](#t3-ott-11-2509){ref-type="table"}), its impact on therapeutic strategies and patients' outcome cannot be overlooked. Our findings suggested that the presence of pulmonary emphysema on CT imaging was an independent indicator of poorer treatment response to first-line chemotherapy in patients with central ADC ([Table 5](#t5-ott-11-2509){ref-type="table"}). On the one hand, recent studies have demonstrated that emphysema was associated with abnormal apoptosis and cell cycle regulation,[@b29-ott-11-2509] which might lead to chemoresistance since regulation of apoptosis was the main mechanism of chemotherapy. On the other hand, epigenetic modifications were common in emphysema,[@b30-ott-11-2509],[@b31-ott-11-2509] which played a crucial role in chemoresistance of lung cancer.[@b32-ott-11-2509],[@b33-ott-11-2509] Moreover, the relationship between emphysema and prognosis suggested a more aggressive form of cancer in these patients,[@b27-ott-11-2509] which might cause poor treatment response to chemotherapy. Besides, the presence of emphysema indicated a poorer physical condition, which limited the treatment options and might lead to lower tolerance to chemotherapy.

In general, the radiological features of central ADC in our study appeared to be aggressive, which might indicate poor prognosis. Studies have proven the relationship between prognosis and the features of ADCs on CT imaging, including the percentage of ground-glass opacity,[@b10-ott-11-2509],[@b34-ott-11-2509],[@b35-ott-11-2509] pleural attachment,[@b36-ott-11-2509],[@b37-ott-11-2509] lymphadenopathy,[@b36-ott-11-2509],[@b37-ott-11-2509] lymphovascular invasion[@b19-ott-11-2509] and so on. Most of these studies did not distinguish central from peripheral ADCs. However, the prognosis of patients with central ADC was different from that of patients with peripheral ADC.[@b16-ott-11-2509]--[@b19-ott-11-2509] Unlike previous studies, most patients in our study were at stage III or IV when they were diagnosed with central lung cancer ([Table 1](#t1-ott-11-2509){ref-type="table"}). The status of lymph node metastasis plays a critical role in predicting prognosis and determining therapeutic strategies in lung cancer.[@b38-ott-11-2509] More than 70% of patients with central ADC in our study were diagnosed with mediastinal lymphadenopathy or hilum lymphadenopathy ([Table 2](#t2-ott-11-2509){ref-type="table"}). Recent studies[@b16-ott-11-2509],[@b17-ott-11-2509] have suggested that the prognosis of patients with central ADC is poorer compared with peripheral ADC, and central ADC is related to a greater rate of nodal metastasis even with a small lesion size. The mechanism underlying the poor prognosis of central ADC may be attributed to the pathologic lymphovascular invasion and other histologic changes.[@b16-ott-11-2509],[@b19-ott-11-2509] Moreover, it has been reported that the 5-year survival rates of patients with NSCLCs with pleural dissemination and separate malignant nodule in the contralateral lung are 2% and 3%, respectively.[@b39-ott-11-2509] In our study, 37.4% and 17.2% of patients with central ADC presented with pleural nodules and interlobular fissure pleural metastasis, respectively ([Table 3](#t3-ott-11-2509){ref-type="table"}), which might also contribute to poor prognosis of central ADC. In a future study, the authors hope to investigate the correlation between the radiological characteristics and the prognosis of patients with central ADCs.

Our study has several limitations. First, this was a retrospective study. Hence, there was a selection bias. In addition, molecular status, such as epidermal growth factor receptor and anaplastic lymphoma kinase, was not included in the analyses, which requires further detailed studies. Besides, the number of patients with some radiological features, such as pulmonary emphysema, interlobular fissure pleural metastasis and lymphangitic carcinomatosis, was limited, which might impair the statistical power of our study. Hence, a larger cohort is required.

Conclusion
==========

Recent studies have revealed that adequate radiological characteristics of lung lesions play a critical role in inferring histologic subtypes, choosing optimal treatment and determining patients' prognosis. In conclusion, our study revealed the distinct clinical and radiological profiles of central pulmonary ADCs in comparison with central SCLCs and SQCCs and the impact of these tumor characteristics on treatment response. Our study may provide an auxiliary and noninvasive method for the differential diagnosis of central lung cancers through their clinical and radiological characteristics. More importantly, our results may be helpful to guide therapeutic strategies of central pulmonary ADC.
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![A receiver operating curve of the levels of CEA.\
**Abbreviations:** AUC, area under the curve; CEA, carcinoembryonic antigen.](ott-11-2509Fig1){#f1-ott-11-2509}

![Representative CT images of central ADC.\
**Notes:** A 61-year-old female presented with (**A**) a primary lesion of central ADC in the left lung (arrow) with interlobular fissure pleural metastasis (arrowheads) and (**B**) a pleural nodule of left parietal pleura (arrow). A 43-year-old male presented with (**C**) a primary lesion of central ADC in the left lung with distal pulmonary atelectasis (arrow), contralateral hilum lymphadenopathy (arrowhead) and (**D**) contralateral lung metastasis (arrows). A 54-year-old male presented with (**E**) a primary lesion of central ADC in the right lung with involvement of right inferior pulmonary vein (arrow) and pleural effusion (arrowheads).\
**Abbreviations:** ADC, adenocarcinoma; CT, computed tomography.](ott-11-2509Fig2){#f2-ott-11-2509}

###### 

Summary of demographic features of patients (N=302)

  Variables                  n (%)
  -------------------------- -------------
  Age, median (range)        61 (36--87)
  Sex                        
   Male                      213 (70.5)
   Female                    89 (29.5)
  Smoking status             
   Smoker                    184 (60.9)
   Nonsmoker                 118 (39.1)
  Pathologic subtypes        
   Adenocarcinoma            99 (32.8)
   Squamous cell carcinoma   95 (31.4)
   Small cell lung cancer    108 (35.8)
  TNM stage                  
   I                         19 (6.3)
   II                        12 (4.0)
   III                       156 (51.6)
   IV                        115 (38.1)

###### 

Associations between clinical features and pathologic types

  Characteristics                                                ADC, n=99             SQCC, n=95            SCLC, n=108            *p*-value   *p*-value, ADC vs SQCC[a](#tfn1-ott-11-2509){ref-type="table-fn"}   *p*-value, ADC vs SCLC[a](#tfn1-ott-11-2509){ref-type="table-fn"}   *p*-value, SQCC vs SCLC[a](#tfn1-ott-11-2509){ref-type="table-fn"}
  -------------------------------------------------------------- --------------------- --------------------- ---------------------- ----------- ------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------
  Age[b](#tfn2-ott-11-2509){ref-type="table-fn"}                 59 (36--81)           63 (43--80)           62 (37--87)            0.005       0.002                                                               0.012                                                               0.543
  Sex                                                                                                                               \<0.001     \<0.001                                                             \<0.001                                                             \<0.001
   Male                                                          44                    90                    79                                                                                                                                                                         
   Female                                                        55                    5                     29                                                                                                                                                                         
  Smoking status                                                                                                                    \<0.001     \<0.001                                                             \<0.001                                                             \<0.001
   Smoker                                                        31                    84                    69                                                                                                                                                                         
   Nonsmoker                                                     68                    11                    39                                                                                                                                                                         
  CEA[b](#tfn2-ott-11-2509){ref-type="table-fn"} (ng/mL)         17.10 (0.28--595.2)   3.37 (0.71--58.09)    3.23 (0.32--167.5)     \<0.001     \<0.001                                                             \<0.001                                                             0.90
  Cyfra21-1[b](#tfn2-ott-11-2509){ref-type="table-fn"} (ng/mL)   6.08 (1.56--84.82)    6.67 (1.29--166.8)    3.68 (0.85--48.34)     \<0.001     0.54                                                                \<0.001                                                             \<0.001
  NSE[b](#tfn2-ott-11-2509){ref-type="table-fn"} (ng/mL)         17.52 (4.42--367.3)   16.02 (8.44--74.77)   51.31 (9.74--508.00)   \<0.001     0.16                                                                \<0.001                                                             \<0.001

**Notes:**

Bonferroni correction in which *p*\<0.0167 is significant.

Continuous quantitative data are presented as median and range.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; Cyfra21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase; SCLC, small cell lung cancer; SQCC, squamous cell carcinoma.

###### 

Associations between CT morphologic features and pathologic types

  Characteristics                                                       ADC, n=99         SQCC, n=95        SCLC, n=108       *p*-value                                         *p*-value, ADC vs SQCC[a](#tfn4-ott-11-2509){ref-type="table-fn"}   *p*-value, ADC vs SCLC[a](#tfn4-ott-11-2509){ref-type="table-fn"}   *p*-value, SQCC vs SCLC[a](#tfn4-ott-11-2509){ref-type="table-fn"}
  --------------------------------------------------------------------- ----------------- ----------------- ----------------- ------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------
  Maximal lesion size[b](#tfn5-ott-11-2509){ref-type="table-fn"} (cm)   4.7 (2.4--13.9)   4.7 (1.4--11.1)   5.7 (3.1--17.5)   0.001                                             0.77                                                                0.003                                                               0.001
  Location                                                                                                                    0.86                                              --                                                                  --                                                                  --
   Left                                                                 47                49                55                                                                                                                                                                                                          
   Right                                                                52                46                53                                                                                                                                                                                                          
  Lobulated margin                                                      25                20                33                0.32                                              --                                                                  --                                                                  --
  Spiculated margin                                                     20                22                11                0.04                                              0.73                                                                0.05                                                                0.01
  Air bronchogram                                                       9                 3                 1                 0.02[c](#tfn6-ott-11-2509){ref-type="table-fn"}   0.13                                                                0.008[c](#tfn6-ott-11-2509){ref-type="table-fn"}                    0.34[c](#tfn6-ott-11-2509){ref-type="table-fn"}
  Bronchovascular bundle convergence                                    13                7                 1                 0.002                                             0.24                                                                \<0.001                                                             0.03[c](#tfn6-ott-11-2509){ref-type="table-fn"}
  Pulmonary infarction                                                  7                 4                 38                \<0.001                                           0.54                                                                \<0.001                                                             \<0.001
  Lymphangitic carcinomatosis                                           9                 1                 7                 0.03[c](#tfn6-ott-11-2509){ref-type="table-fn"}   0.02[c](#tfn6-ott-11-2509){ref-type="table-fn"}                     0.61                                                                0.07[c](#tfn6-ott-11-2509){ref-type="table-fn"}
  Pulmonary emphysema                                                   12                29                23                0.007                                             0.003                                                               0.10                                                                0.15
  Mediastinal lymphadenopathy                                           82                62                84                0.01                                              0.006                                                               0.39                                                                0.06
  Contralateral hilum lymphadenopathy                                   23                3                 9                 \<0.001                                           \<0.001                                                             0.004                                                               0.14
  Ipsilateral hilum lymphadenopathy                                     71                57                76                0.16                                              --                                                                  --                                                                  --
  Contralateral lung metastasis                                         29                6                 4                 \<0.001                                           \<0.001                                                             \<0.001                                                             0.52[c](#tfn6-ott-11-2509){ref-type="table-fn"}
  Pleural nodules                                                       37                5                 12                \<0.001                                           \<0.001                                                             \<0.001                                                             0.20
  Interlobular fissure pleural metastasis                               17                0                 2                 \<0.001                                           \<0.001                                                             \<0.001                                                             0.50[c](#tfn6-ott-11-2509){ref-type="table-fn"}
  Pleural effusion                                                      55                24                46                \<0.001                                           \<0.001                                                             0.07                                                                0.01
  Vascular involvement                                                  32                39                83                \<0.001                                           0.23                                                                \<0.001                                                             \<0.001

**Notes:**

Bonferroni correction in which *p*\<0.0167 is significant.

Continuous quantitative data are presented as median and range.

Fisher's exact test.

**Abbreviations:** ADC, adenocarcinoma; CT, computed tomography; SCLC, small cell lung cancer; SQCC, squamous cell carcinoma.

###### 

Clinical and radiological characteristics discriminating SQCC and SCLC from ADC in central lung adenocarcinoma via multivariate logistic regression analysis

  Characteristics                       SQCC vs ADC          SCLC vs ADC                        
  ------------------------------------- -------------------- ------------- -------------------- ---------
  Age                                   1.06 (1.00--1.11)    0.03          1.07 (1.01--1.12)    0.01
  Sex                                                                                           
   Male                                 5.44 (1.33--22.24)   0.02          2.16 (0.53--8.90)    0.29
   Female                               Reference                          Reference            
  Smoking status                                                                                
   Nonsmoker                            0.18 (0.05--0.64)    0.01          0.42 (0.11--1.65)    0.21
   Smoker                               Reference                          Reference            
  CEA                                   0.94 (0.90--0.98)    0.002         0.98 (0.96--1.00)    0.02
  Cyfra21-1                             1.03 (1.00--1.07)    0.07          0.56 (0.45--0.70)    \<0.001
  NSE                                   0.95 (0.91--0.98)    0.06          1.04 (1.02--1.06)    \<0.001
  Maximal lesion size                   0.83 (0.63--1.10)    0.19          1.23 (0.90--1.68)    0.19
  Pulmonary infarction                                                                          
   No                                   4.11 (0.72--23.43)   0.11          0.76 (0.19--3.05)    0.69
   Yes                                  Reference                          Reference            
  Contralateral hilum lymphadenopathy                                                           
   No                                   8.85 (1.28--61.04)   0.03          1.14 (0.21--6.27)    0.88
   Yes                                  Reference                          Reference            
  Pleural nodules                                                                               
   No                                   3.87 (0.86--17.44)   0.08          4.57 (1.27--16.38)   0.02
   Yes                                  Reference                          Reference            
  Vascular involvement                                                                          
   No                                   0.69 (0.38--1.23)    0.21          0.12 (0.04--0.36)    \<0.001
   Yes                                  Reference                          Reference            

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; Cyfra21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase; OR, odds ratio; SCLC, small cell lung cancer; SQCC, squamous cell carcinoma.

###### 

Associations of clinical and CT features with treatment response of central ADC using univariate and multivariate logistic regression models

  Characteristics                                                       Response group, n=42   Nonresponse group, n=43   Univariate analysis   Multivariate analysis                        
  --------------------------------------------------------------------- ---------------------- ------------------------- --------------------- ----------------------- -------------------- ------
  Age[a](#tfn9-ott-11-2509){ref-type="table-fn"}                        59 (38--79)            58 (36--81)               1.01 (0.97--1.06)     0.57                    1.03 (0.97--1.08)    0.34
  Sex                                                                                                                                                                                       
   Male                                                                 18                     20                        Reference                                     --                   --
   Female                                                               24                     23                        0.86 (0.37--2.03)     0.74                    1.51 (0.44--5.21)    0.52
  Smoking status                                                                                                                                                                            
   Nonsmoker                                                            30                     28                        Reference                                     --                   --
   Smoker                                                               12                     15                        1.34 (0.54--3.35)     0.53                    1.51 (0.40--5.61)    0.54
  Tumor stage                                                                                                                                                                               
   I--III                                                               24                     18                        Reference                                     --                   --
   IV                                                                   18                     25                        1.85 (0.78--4.38)     0.16                    2.07 (0.82--5.18)    0.12
  CEA[a](#tfn9-ott-11-2509){ref-type="table-fn"} (ng/mL)                24.67 (0.66--286.50)   6.73 (0.28--595.20)       1.00 (0.99--1.01)     0.31                    --                   --
  Cyfra21-1[a](#tfn9-ott-11-2509){ref-type="table-fn"} (ng/mL)          7.02 (1.90--45.35)     5.50 (1.56--84.82)        0.99 (0.95--1.03)     0.67                    --                   --
  NSE[a](#tfn9-ott-11-2509){ref-type="table-fn"} (ng/mL)                20.50 (4.42--61.54)    17.11 (11.09--367.30)     1.00 (0.98--1.01)     0.50                    --                   --
  Maximal lesion size[a](#tfn9-ott-11-2509){ref-type="table-fn"} (cm)   4.8 (2.6--7.8)         5.0 (2.6--13.9)           0.84 (0.64--1.11)     0.22                    --                   --
  Location                                                                                                                                                             --                   --
   Left                                                                 21                     19                        Reference                                     --                   --
   Right                                                                21                     24                        1.26 (0.54--2.97)     0.59                    --                   --
  Lobulated margin                                                      8                      11                        1.46 (0.52--4.10)     0.47                    --                   --
  Spiculated margin                                                     8                      8                         0.97 (0.33--2.88)     0.96                    --                   --
  Air bronchogram                                                       5                      4                         0.76 (0.19--3.05)     0.70                    --                   --
  Bronchovascular bundle convergence                                    6                      5                         0.79 (0.22--2.82)     0.72                    --                   --
  Pulmonary infarction                                                  3                      4                         1.33 (0.28--6.35)     0.72                    --                   --
  Lymphangitic carcinomatosis                                           3                      5                         1.71 (0.38--7.66)     0.48                    --                   --
  Pulmonary emphysema                                                   2                      9                         5.29 (1.07--26.19)    0.04                    8.04 (1.39--46.37)   0.02
  Ipsilateral hilum lymphadenopathy                                     35                     30                        0.46 (0.16--1.31)     0.15                    --                   --
  Contralateral hilum lymphadenopathy                                   11                     12                        1.10 (0.42--2.84)     0.86                    --                   --
  Mediastinal lymphadenopathy                                           37                     35                        0.59 (0.18--1.98)     0.39                    --                   --
  Contralateral lung metastasis                                         16                     10                        0.49 (0.19--1.26)     0.14                    --                   --
  Pleural nodules                                                       17                     14                        0.71 (0.29--1.72)     0.45                    --                   --
  Interlobular fissure pleural metastasis                               7                      9                         1.32 (0.44--3.96)     0.61                    --                   --
  Pleural effusion                                                      22                     27                        1.53 (0.65--3.65)     0.33                    --                   --
  Vascular involvement                                                  12                     15                        1.34 (0.54--3.35)     0.53                    --                   --

**Note:**

Continuous quantitative data are presented as median and range.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; CT, computed tomography; Cyfra21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase; OR, odds ratio.
